DailyIQ
Last updated 1 hour ago

MTD·Mettler-Toledo International Inc.

$.
-. (-.%)
High
$1,106.86
Open
$1,098.46
Market Cap
22.29B
52W High
$1,525.17
Low
$1,088.51
P. Close
$1,103.09
P/E
25.47
52W Low
$1,023.05
Fwd P/E
102.26
Mean Target
-
Technical Score (1D)
27
SELL
News Sentiment
-
NO DATA
No summary available yet.
Earnings Summary
Mettler-Toledo International Inc. is a global provider of precision instruments and services, operating in the Healthcare sector's Diagnostics & Research industry. The company serves diverse industries across the Americas, Europe, and Asia with laboratory and industrial instruments, including analytical tools, balances, weighing equipment, and inspection systems. Mettler-Toledo's business model relies on a broad customer base in sectors such as life sciences and food production, supported by its extensive sales and distribution network. Analyzing Mettler-Toledo's recent earnings, the company demonstrated consistent positive performance in both EPS and revenue over the last four reported quarters. For Q4 2025, EPS was $13.36 against an estimate of $12.93, and revenue was $1.13 billion against an estimate of $1.116 billion. This followed a Q1 2026 where EPS was $8.91, beating the estimate of $8.79, and revenue was $947.13 million, slightly missing the estimate of $951.22 million. The trend shows a pattern of exceeding earnings expectations, with revenue performance being more mixed in the most recent quarter. Historically, Mettler-Toledo has shown a strong year-over-year growth trajectory, consistently beating analyst estimates for earnings per share in the quarters where data is available for comparison. For instance, Q4 2025 EPS of $13.36 surpassed the estimate of $12.93, and Q1 2026 EPS of $8.91 exceeded the estimate of $8.79. While revenue estimates were not consistently provided for all past quarters, the available data suggests a generally positive revenue trend, with a slight miss in the most recent Q1 2026 report. Recent news highlights Mettler-Toledo's strong financial health, characterized by high profitability and a robust return on invested capital, suggesting potential for sustained growth. However, concerns have been raised regarding the impact of accelerating wholesale inflation, which could increase operating costs and potentially lead to heightened regulatory scrutiny. Analyst sentiment remains cautiously optimistic, with a maintained Buy rating from Stifel, though the price target was lowered, indicating a recalibration of valuation expectations. Looking ahead, investors will be watching for Mettler-Toledo's ability to manage potential cost increases stemming from inflation and to maintain its strong profitability. Key will be the company's performance in passing on costs to customers and its continued operational execution in its core laboratory and industrial segments. Further clarity on the reasoning behind the recent analyst price target adjustment will also be a point of interest for stakeholders.

EPS

EstBeatMiss
$7.06$8.84$10.62$12.40$14.18Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$10.79 - -
Q1'26$8.79$8.91+1.4%
Q4'25$12.93$13.36+3.3%
Q3'25$10.66$11.15+4.6%
Q2'25$9.60$10.09+5.1%
Q1'25$7.88$8.19+3.9%

Revenue

EstBeatMiss
$847M$927M$1.0B$1.1B$1.2BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.0B - -
Q1'26$951M$947M-0.4%
Q4'25$1.1B$1.1B+1.3%
Q3'25 - $1.0B -
Q2'25 - $983M -
Q1'25 - $884M -

Market Data

MTD Stock Snapshot

MTD is currently trading at $1095.92, giving Mettler-Toledo International Inc. a market cap of 22.29B and a P/E ratio of 25.5. Today's range spans $1088.51–$1106.86, with shares opening at $1098.46 and moving down $7.17 (0.6%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL).

Over the past year MTD has traded between $1023.05 and $1525.17 - the current price is +7.1% off the 52-week low and -28.1% from the high.

Sector rotation is working against MTD - large-cap, Healthcare, 22.29B market cap. Technical score 27/100 (SELL), sentiment neutral (-/100), price $1095.92 (near 52-week lows). (P/E: 25.5) When capital rotates out of a sector, large-cap names with bearish technicals are the first to absorb the selling. Annual range $1023.05–$1525.17 frames where the next potential demand zone resides.

Analyst coverage for MTD becomes a double-edged factor in a SELL phase: at 22.29B in Healthcare market cap, active coverage is high enough that downgrade risk is real and impactful. The 27/100 technical reading and neutral sentiment (-/100) at $1095.92 (near 52-week lows) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $1023.05–$1525.17 range establishes where that repricing lands.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…